Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

5 Customer Reviews

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

  • J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Arch Toxicol, 2018, 92(4):1435-1451. Pazopanib purchased from Selleck.

  • (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

  • (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell M2fBfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYGzfFlxUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;Mj64PYUuODVizszN MX3TRW5ITVJ?
human AN3-CA cell NVuwUnN5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlA2KG6P MkDSV2FPT0WU
human CGTH-W-1 cell MlHYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUTJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFAvODFibl2= MlT4V2FPT0WU
human GDM-1 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGdFVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCzMlk6KG6P MUjTRW5ITVJ?
human A204 cell M3vRUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoDyTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC5MlA3KG6P MYTTRW5ITVJ?
human G-402 cell NUn5epRbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVXCd5dnUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU{OS56NDDuUS=> M2fCfnNCVkeHUh?=
human MFE-296 cell MmTBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYrp[G4yUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlk3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53OUCyNkDPxE1? NXrKTldnW0GQR1XS
human NOS-1 cell NELWWlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLPPI9jUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCrY{WwQVAvPjV7OEeg{txO NHy1W5RUSU6JRWK=
human KG-1 cell Mn\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml3tTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NVc2PSEQvF2= M4LoZ3NCVkeHUh?=
human HT55 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXH0b4p3UW6qaXLpeIlwdiCxZjDoeY1idiCKVEW1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDd6MTFOwG0> MWnTRW5ITVJ?
human MG-63 cell M4PX[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLFVIFKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xODF2NjFOwG0> NIG1[3RUSU6JRWK=
human CCF-STTG1 cell M360Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGNETi2VVGTHNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS5yNEm4NUDPxE1? MnHvV2FPT0WU
human RT-112 cell NVrsUFk4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlSzTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlExOzd4IN88US=> NU\zOJpjW0GQR1XS
human MC-IXC cell Mn[1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DoeGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yOTVzMjFOwG0> MXjTRW5ITVJ?
human HUTU-80 cell NGTQPYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlPKTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zQDFyMzFOwG0> NG\MXpNUSU6JRWK=
human MV-4-11 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4\vR2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzR3MEGg{txO NIfkOW1USU6JRWK=
human LCLC-103H cell NXvTZ4pRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NY\2dldoUW6qaXLpeIlwdiCxZjDoeY1idiCOQ1zDMVExO0hiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= MUnTRW5ITVJ?
human G-401 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEC5XohKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> MYPTRW5ITVJ?
human A704 cell NFXwTFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFf0cmtKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxOzJ|IN88US=> NHXqXlNUSU6JRWK=
human ESS-1 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnDWZZjUW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjB|OU[g{txO NEfQUWhUSU6JRWK=
human HLE cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP NFewRldUSU6JRWK=
human NY cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfrNmhKdmirYnn0bY9vKG:oIHj1cYFvKE6\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64OFgzOSEQvF2= M3;DWnNCVkeHUh?=
human A427 cell Ml\lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWq2WFd6UW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46QDB5NTFOwG0> MXTTRW5ITVJ?
human SK-N-DZ cell NIW2PFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzOzhzIN88US=> M33MTnNCVkeHUh?=
human J82 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGo5OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwME[wPFgh|ryP NGS2bVFUSU6JRWK=
human GI-1 cell M3HHSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnTDTY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNlk2OSEQvF2= M{H0VnNCVkeHUh?=
human NCI-H716 cell NFTK[GJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTNUoxKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|E3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MU[zN{DPxE1? MoXNV2FPT0WU
human SF126 cell NYjlV2ZVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rxeWlvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ4PDV7IN88US=> NF7Q[IJUSU6JRWK=
human H4 cell NFK3TVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIji[mhKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= MoG4V2FPT0WU
human LB831-BLC cell NVnjTId3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWDJcohq[mm2aX;uJI9nKGi3bXHuJGxDQDNzLVLMR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTR3Nk[g{txO MmrxV2FPT0WU
human HCC1395 cell MmXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTjTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzM{m1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42QDF3NjFOwG0> M1[1TXNCVkeHUh?=
human LK-2 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[0OVY6KM7:TR?= M1nXUHNCVkeHUh?=
human G-361 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWHYSYtVUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODRyOEKg{txO M3G4dHNCVkeHUh?=
human NCI-H2342 cell Ml;QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfkdmJFUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1|LkGzN|E3KM7:TR?= M3fEcHNCVkeHUh?=
human SK-LU-1 cell  NWrWeG96T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE5PzZ5IN88US=> M1XtcXNCVkeHUh?=
human IGROV-1 cell  MmXlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIPO[3hKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ2N{GzJO69VQ>? M37teXNCVkeHUh?=
human EB2 cell MmrDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2PmVmlvcGmkaYTpc44hd2ZiaIXtZY4hTUJ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6yPFE3QCEQvF2= MV3TRW5ITVJ?
human CAL-54 cell NYLoXmxVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWLDWpBXUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ6M{[3JO69VQ>? M1W3Z3NCVkeHUh?=
human LB1047-RCC cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV21b3FIUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjN|MUO2PEDPxE1? MVPTRW5ITVJ?
Daudi cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWD1Z5JOUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61N|E3PCEQvF2= NFLXTXNUSU6JRWK=
human Daudi cell M2fsOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHfCbItKdmirYnn0bY9vKG:oIHj1cYFvKESjdXTpJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43PjJzOTFOwG0> NV2wSmtQW0GQR1XS
human A172 cell NXPZUphoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPsTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz63N|c6KM7:TR?= MmT2V2FPT0WU
human KGN cell NITybo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXUTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkC2O|A6KM7:TR?= MmDMV2FPT0WU
human SNG-M cell Ml;QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlTqTY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PjlizszN MlHMV2FPT0WU
human SW1710 cell M2T1dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1vPfWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> M1noW3NCVkeHUh?=
human HT29 cells NHP1VGlRem:uaX\ldoF1cW:wIHHzd4F6 NHLSToZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= Mn22NVg3OjB|OEK=
human A375P cells NXPJOFBGWHKxbHnm[ZJifGmxbjDhd5NigQ>? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{XQJINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv M37ke|E5PjJyM{iy
human HN5 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 NFrUbolCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= NGrufXEyQDZ{MEO4Ni=>
HUVEC NH7BZXZHfW6ldHnvckBie3OjeR?= NU\KVVVnOSEQvF2= MnrpOkBp MlnlRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvckBifCByLkGgeW0h[W[2ZYKgOkBpenNiYomgUYF1emmpZXygZZN{[Xl? M3fJZ|I1ODN4MESy
human Daoy cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NI\lfFVKdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc4QTR7IN88US=> MV3TRW5ITVJ?
human DMS-273 cell NVPxfWVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk3OjB{IN88US=> MlfOV2FPT0WU
human KU812 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYr2d4d1UW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzd6MUKg{txO NF3XSoZUSU6JRWK=
human NCI-H727 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;pNWcxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEC5NFEh|ryP MmnjV2FPT0WU
human P30-OHK cell M{DGS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN MXnTRW5ITVJ?
human MIA-PaCa-2 cell NWHCVYVoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mne5TY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MES2OkDPxE1? NEf6Z5VUSU6JRWK=
human TT cell M2TqN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGT1bZRKdmirYnn0bY9vKG:oIHj1cYFvKFSWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OlI1KM7:TR?= MnXoV2FPT0WU
human DK-MG cell NEnvNnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH;H[HVKdmirYnn0bY9vKG:oIHj1cYFvKESNLV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB{ODFOoI0> MkXzV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT02979899 Completed Biological: TRC105|Drug: Votrient Advanced Angiosarcoma Tracon Pharmaceuticals Inc. February 13 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID